Promega

Companies Promega

News Promega

• Promega and BASF develop alternative method on identifying allergenic substances

  Promega and BASF have jointly developed an alternative method to animal studies that can reliably detect the allergenic potential of substances. Using a newly developed cell line, the reaction of skin cells to allergenic substances can now be demonstrated in the test tube. Allergic skin reactions in more

• Horizon Discovery Announces Strategic Partnership with Promega to Develop Next-Generation Predictive Human Disease Models

  Horizon Discovery Ltd.  announced a strategic partnership agreement with Promega Corporation. The partnership centers on the delivery of endogenous gene reporting capabilities, in the form of Promega’s luciferase and HaloTag® reporter technologies, using Horizon’s proprietary homologous recombinatio more

• Promega and Leica Microsystems Sign Agreement to Develop Fluorescent Ligands Enabling Live Cell Imaging at the Sub 100 nm Range

  Promega Corp. announced that it has signed an agreement with Leica Microsystems to enable fluorescent imaging of proteins in live cells. Under the terms of the agreement, Promega will develop fluorescent ligands for its HaloTag fusion proteins, that will be used to label proteins within live cells s more

White papers Promega

• Trichostatin A Treatment of Cells Transfected with FuGENE® HD Transfection Reagent
  

  Treatment of eukaryotic cells with trichostatin A (TSA) - a broad-spectrum inhibitor of histone deacetylation - is frequently used in studies of epigenetic regulation of gene expression. To be able to investigate the effects of TSA on promoter activity in reporter gene assays it is necessary to secure high transfection efficiency and low toxicity of the transfection reagent. In this study we tested transfection efficiency and toxicity of FuGENE® HD Transfection Reagent in experiments with hepatoma cell line HepG2. We also established a protocol for TSA treatment that guarantees high cell survival and sufficient TSA effect more

• Transfection of T47D Mammary Carcinoma Cells Using FuGENE HD® Transfection Reagent
  

  Despite advances in transfection reagents and methods, there are still a number of cell lines which are difficult to transfect, such as T47D mammary carcinoma cells. Using a ß-galactosidase reporter plasmid, the transfection of T47D cells with FuGENE® HD Transfection Reagent has been optimized. Using a variety of FuGENE® HD Transfection Reagent-to-DNA ratios, we have shown through RT-PCR and ß-galactosidase enzyme activity assays that FuGENE® HD Transfection Reagent is able to transfect this cell line with high efficiency. more

• Advances in Transfection Technologies: Using FuGENE® HD Transfection Reagent with PCR Constructs
  

  With recent advances in molecular biology, it is now possible to construct genomic sequences and then evaluate the protein produced by those sequences. Ever-increasing portions of the genome are being investigated for their functions or for the effect sequence changes might have on them. Such study may entail testing the function of an unknown region of the genome, or mutating a sequence in a particular region to see how protein function or binding to other molecules might be affected. In these cases, using a complete plasmid for transfection is tedious, requiring time-consuming cloning, amplification, and purification of a plasmid construct. If multiple variants are to be tested, it would be much simpler if the PCR product could be tested directly, and a plasmid construct made only once the sequence of interest is identified. more

Publications Promega

• Construction and Expression of Oligonucleotide-Based Antisense Cassettes

  INTRODUCTION This protocol describes simple and robust methods for the construction and cloning of expression constructs that can be used to deliver antisense effectors, exemplified by the hammerhead ribozyme and short hairpin RNA (shRNA), into cultured cell lines. The protocol also describes the c more

• Engineering of a wheat germ expression system to provide compatibility with a high throughput pET-based cloning platform

  Wheat germ cell-free methods provide an important approach for the production of eukaryotic proteins. We have developed a protein expression vector for the TNT® SP6 High-Yield Wheat Germ Cell-Free (TNT WGCF) expression system (Promega) that is also compatible with our T7-based Escherichia coli intra more

• Expression, One-Step Purification, and Immobilization of HaloTagTM Fusion Proteins on Chloroalkane-Functionalized Magnetic Beads

  The presented work introduces a novel method to immobilize enzymes either purified or directly out of a crude extract onto magnetic particles in the micrometer range. This method is based on the creation of a fusion protein consisting of the enzyme of choice and a mutant dehalogenase. The dehalogena more

Market studies Promega

• Qiagen N.V. (QIA) - Product Pipeline Analysis

  Qiagen N.V. (QIA) - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the Qiagen N.V. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, more

• Kreatech Holding B.V. - Strategic SWOT Analysis Review

  Kreatech Holding B.V. - Strategic SWOT Analysis Review Summary Kreatech Holding B.V. (Kreatech Diagnostics) is a privately-held molecular diagnostics company. It is engaged in the development, manufacture and marketing of innovative labeling and detection products for applications in diagnostic an more

Websites Promega